Vivian P. Thompson

Mar 29, 2024 | digitalcommons.library.tmc.edu | Rury R Holman |M Angelyn Bethel |Robert J. Mentz |Vivian P. Thompson

BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly.